GENPF (Genix Pharmaceuticals) EPS without NRI: $-0.01 (TTM As of Apr. 2026)


What is Genix Pharmaceuticals EPS without NRI?

Genix Pharmaceuticals GENPF EPS without NRI is $-0.01 as of Apr. 2026. The stock has 3 warning signs investors should review. Among 786 Drug Manufacturers companies, Genix Pharmaceuticals ranks better than 65.65% on this metric.

Genix Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Apr. 2026 was $0.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.01.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 19.30% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 23.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Genix Pharmaceuticals's EPS without NRI or its related term are showing as below:

GENPF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -210.7   Med: 13.45   Max: 62.5
Current: 19.3

During the past 13 years, Genix Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 62.50% per year. The lowest was -210.70% per year. And the median was 13.45% per year.

GENPF's 3-Year EPS without NRI Growth Rate is ranked better than
65.65% of 786 companies
in the Drug Manufacturers industry
Industry Median: 9.6 vs GENPF: 19.30

Genix Pharmaceuticals's EPS (Diluted) for the three months ended in Apr. 2026 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.01.

Genix Pharmaceuticals's EPS (Basic) for the three months ended in Apr. 2026 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.01.


Genix Pharmaceuticals  (OTCPK:GENPF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Genix Pharmaceuticals EPS without NRI Related Terms


Genix Pharmaceuticals EPS without NRI Historical Data

* Premium members only.

The historical data trend for Genix Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genix Pharmaceuticals EPS without NRI Chart

Genix Pharmaceuticals Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.01 -0.01 -0.00 -0.01

Genix Pharmaceuticals Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.01 0.00 0.00

GENPF vs ZTS, UTHR: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Genix Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genix Pharmaceuticals PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genix Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Genix Pharmaceuticals's PE Ratio without NRI falls into.



Genix Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-0.01 mean?
Genix Pharmaceuticals (GENPF) has a EPS without NRI of $-0.01 as of Apr. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Genix Pharmaceuticals and its competitors. According to the industry distribution chart, Genix Pharmaceuticals ranks #270 out of 786 companies in the Drug Manufacturers industry, placing it in the top 34.4%.
Is Genix Pharmaceuticals' EPS without NRI too high?
Genix Pharmaceuticals' current EPS without NRI is $-0.01. Based on the distribution chart, Genix Pharmaceuticals ranks #270 out of 786 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Genix Pharmaceuticals' EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genix Pharmaceuticals ranks #270 out of 786 companies for EPS without NRI. This puts Genix Pharmaceuticals in the upper half of its industry. The industry median EPS without NRI is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Genix Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genix Pharmaceuticals's current EPS without NRI is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genix Pharmaceuticals stock overvalued right now?
Genix Pharmaceuticals (GENPF) has a current EPS without NRI of $-0.01. The current EPS without NRI is $-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Genix Pharmaceuticals (GENPF), the current EPS without NRI is $-0.01 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genix Pharmaceuticals Business Description

Other Exchanges GENX:Canada
Address 1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 1J8
Genix Pharmaceuticals Corp is a Canadian life sciences company focused on the research, development, manufacturing, sales, and distribution of novel, branded generic ophthalmic drugs, and ophthalmic OTC products. It operates as a formulator, manufacturer, licensor, and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its ophthalmic products portfolio comprises different kinds of eye ointments (pending approval), and eye drops. Geographically the company operates only in Canada.